Aevi Genomic Medicine, Inc.: 10-Q filed 2014-05-08

Name: Aevi Genomic Medicine, Inc.: 10-Q filed 2014-05-08
Creator: Aevi Genomic Medicine, Inc.

What Aevi Genomic Medicine, Inc. reported in its quarterly report filed 2014-05-08 (fiscal Q1 2014): 22 published measures, 56 facts as tagged in accession 0001144204-14-028382.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-05-08
Fiscal period: fiscal Q1 2014
Accession: 0001144204-14-028382 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Aevi Genomic Medicine, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-03-31	20,251,000	USD
At 2013-12-31	23,087,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-03-31	4,657,000	USD
At 2013-12-31	4,664,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2014-03-31	15,594,000	USD
At 2013-12-31	18,423,000	USD
At 2013-03-31	28,544,000	USD
At 2012-12-31	1,934,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-03-31	19,141,000	USD
At 2013-12-31	22,390,000	USD
At 2013-03-31	32,463,000	USD
At 2012-12-31	6,431,000	USD
At 2000-01-26	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	-5,357,000	USD	90
2000-01-27 to 2014-03-31	-87,491,000	USD	5178
2013-01-01 to 2013-03-31	-3,679,000	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	3,989,000	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	24,000	USD	90
2000-01-27 to 2014-03-31	2,292,000	USD	5178
2013-01-01 to 2013-03-31	37,000	USD	90

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	18,872,001	shares	90
2013-01-01 to 2013-03-31	15,222,268	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	18,872,001	shares	90
2013-01-01 to 2013-03-31	15,634,768	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	-0.28	USD/shares	90
2013-01-01 to 2013-03-31	-0.24	USD/shares	90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	-0.28	USD/shares	90
2013-01-01 to 2013-03-31	-0.29	USD/shares	90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	5,000	USD	90
2000-01-27 to 2014-03-31	117,000	USD	5178
2013-01-01 to 2013-03-31	3,000	USD	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-03-31	337,000	USD
At 2013-12-31	357,000	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	-5,235,000	USD	90
2000-01-27 to 2014-03-31	-83,013,000	USD	5178
2013-01-01 to 2013-03-31	-4,577,000	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-03-31	19,773,000	USD
At 2013-12-31	22,592,000	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-03-31	2,877,000	USD
At 2013-12-31	3,014,000	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	2,142,000	USD	90
2000-01-27 to 2014-03-31	38,708,000	USD	5178
2013-01-01 to 2013-03-31	2,031,000	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-03-31	18,751,591	shares
At 2013-12-31	18,497,307	shares

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	-5,352,000	USD	90
2000-01-27 to 2014-03-31	-87,374,000	USD	5178
2013-01-01 to 2013-03-31	-3,676,000	USD	90

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	5,357,000	USD	90
2013-01-01 to 2013-03-31	3,679,000	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	3,093,000	USD	90
2000-01-27 to 2014-03-31	47,209,000	USD	5178
2013-01-01 to 2013-03-31	2,546,000	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-01-01 to 2014-03-31	44,000	USD	90
2000-01-27 to 2014-03-31	1,447,000	USD	5178
2013-01-01 to 2013-03-31	39,000	USD	90

Inspect the source

Entity: Aevi Genomic Medicine, Inc. / CIK 0001138776
Captured: 2026-09-23 02:47 UTC
SEC response SHA-256: 16af7d8db7e8763eb25a11447dbdb1790b536242dd21d662c54ec3da77f91124

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001138776.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))